• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.

作者信息

Masera Nicoletta, Tavecchia Luisa, Longoni Daniela Valentina, Maglia Oscar, Biondi Andrea, Masera Giuseppe

机构信息

Paediatric Clinic, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy.

出版信息

Blood Transfus. 2011 Oct;9(4):462-5. doi: 10.2450/2011.0098-10. Epub 2011 Jul 18.

DOI:10.2450/2011.0098-10
PMID:21839013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3200417/
Abstract
摘要

相似文献

1
Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.去铁酮所致粒细胞缺乏症：一例伴有骨髓细胞形态学和功能检查的病例报告
Blood Transfus. 2011 Oct;9(4):462-5. doi: 10.2450/2011.0098-10. Epub 2011 Jul 18.
2
Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Oct;108(4):e13-9. doi: 10.1016/j.tripleo.2009.06.021.
3
Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.
Lancet. 1989 Aug 19;2(8660):457. doi: 10.1016/s0140-6736(89)90641-7.
4
Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation.
Lancet. 1990 Apr 21;335(8695):970. doi: 10.1016/0140-6736(90)91031-5.
5
Deferiprone-associated myelotoxicity.去铁酮相关的骨髓毒性。
Eur J Haematol. 1994 Nov;53(5):298-301. doi: 10.1111/j.1600-0609.1994.tb01323.x.
6
Agranulocytosis with deferiprone treatment of superficial siderosis.去铁酮治疗浅表性铁沉积症并发粒细胞缺乏症
BMJ Case Rep. 2013 Aug 7;2013:bcr2013010099. doi: 10.1136/bcr-2013-010099.
7
Deferiprone in iron overload.
N Engl J Med. 1995 Aug 31;333(9):598-9.
8
Development of oral iron chelator L1.
Lancet. 1993 Apr 24;341(8852):1088-9. doi: 10.1016/0140-6736(93)92444-x.
9
Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.特异质性药物诱导的粒细胞缺乏症：去铁酮的范例
Hemoglobin. 2010 Jun;34(3):291-304. doi: 10.3109/03630269.2010.484791.
10
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.口服铁螯合剂去铁酮在中国依赖输血的地中海贫血儿童中的安全性概况
Curr Drug Saf. 2016;11(2):137-44. doi: 10.2174/1574886310666150930113957.

引用本文的文献

1
Iron Overload, Clonal Hematopoiesis, and Cancer Risk in Aging and Transfusion-Dependent Populations: A Literature Review.衰老及输血依赖人群中的铁过载、克隆性造血与癌症风险：文献综述
Cureus. 2025 Jun 13;17(6):e85936. doi: 10.7759/cureus.85936. eCollection 2025 Jun.
2
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.地拉罗司治疗患者的严重中性粒细胞减少症和感染风险率：28 年的数据。
Blood Adv. 2024 Nov 12;8(21):5641-5649. doi: 10.1182/bloodadvances.2023012316.
3
Deferiprone-induced agranulocytosis: 20 years of clinical observations.去铁酮诱导的粒细胞缺乏症：20年临床观察
Am J Hematol. 2016 Oct;91(10):1026-31. doi: 10.1002/ajh.24479. Epub 2016 Aug 4.
4
Agranulocytosis with deferiprone treatment of superficial siderosis.去铁酮治疗浅表性铁沉积症并发粒细胞缺乏症
BMJ Case Rep. 2013 Aug 7;2013:bcr2013010099. doi: 10.1136/bcr-2013-010099.
5
Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.去铁酮治疗输血依赖型地中海贫血患者的安全性和有效性。
Ther Adv Hematol. 2012 Oct;3(5):299-307. doi: 10.1177/2040620712450252.

本文引用的文献

1
Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.特异质性药物诱导的粒细胞缺乏症：去铁酮的范例
Hemoglobin. 2010 Jun;34(3):291-304. doi: 10.3109/03630269.2010.484791.
2
Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone.从去铁胺转换为去铁胺与地拉罗司联合螯合疗法后，重型地中海贫血患者的生存率得到提高。
Haematologica. 2009 Dec;94(12):1777-8. doi: 10.3324/haematol.2009.009118. Epub 2009 Oct 8.
3
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.长期序贯使用去铁酮-去铁胺与单独使用去铁酮治疗重型地中海贫血患者：一项随机临床试验。
Br J Haematol. 2009 Apr;145(2):245-54. doi: 10.1111/j.1365-2141.2009.07609.x. Epub 2009 Feb 19.
4
Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance.英国重型地中海贫血患者生存率的提高及其与T2*心血管磁共振成像的关系
J Cardiovasc Magn Reson. 2008 Sep 25;10(1):42. doi: 10.1186/1532-429X-10-42.
5
Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.一名重型地中海贫血患者出现发热性中性粒细胞减少症和出血性中风。
Hemoglobin. 2007;31(4):499-501. doi: 10.1080/03630260701641211.
6
Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.
Blood. 2007 Jun 15;109(12):5157-9. doi: 10.1182/blood-2007-02-065805. Epub 2007 Mar 7.
7
Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.去铁胺与去铁酮联合治疗重型β地中海贫血输血性铁过载患者。
Ann Hematol. 2006 May;85(5):315-9. doi: 10.1007/s00277-005-0075-z. Epub 2006 Feb 1.
8
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major.接受去铁胺或去铁酮治疗的重型地中海贫血患者的心脏发病率和死亡率。
Blood. 2006 May 1;107(9):3733-7. doi: 10.1182/blood-2005-07-2933. Epub 2005 Dec 22.
9
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.去铁酮或去铁胺治疗重型β地中海贫血无症状心肌铁沉积患者的随机对照试验
Blood. 2006 May 1;107(9):3738-44. doi: 10.1182/blood-2005-07-2948. Epub 2005 Dec 13.
10
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.口服铁螯合剂去铁酮长期治疗的安全性和有效性。
Blood. 2003 Sep 1;102(5):1583-7. doi: 10.1182/blood-2002-10-3280. Epub 2003 May 22.